Additionally, targeting ERBB2 (such as the use of Trastuzumab) could be an effective treatment for patients originally diagnosed with luminal A breast cancer with subsequently found to exhibit luminal B-ERBB2+ characteristics and resistance to endocrine therapy after prolonged treatment. This evidence concerns the gene ERBB2 and breast cancer.